Nektar Therapeutics Forecast, price target & analysts
Nektar Therapeutics Target price 2025 - Analyst rating & recommendation
Nektar Therapeutics Classifications & Recommendation:
Nektar Therapeutics Price Target
| Target Price | $4.13 |
| Price | $0.80 |
| Potential |
419.13%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Nektar Therapeutics 2026 .
The average Nektar Therapeutics target price is $4.13.
This is
419.13%
register free of charge
$7.00
779.18%
register free of charge
$1.30
63.28%
register free of charge
|
|
| A rating was issued by 9 analysts: 4 Analysts recommend Nektar Therapeutics to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nektar Therapeutics stock has an average upside potential 2026 of
419.13%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 90.12 | 105.93 |
| 2.11% | 17.55% | |
| EBITDA Margin | -143.82% | -141.72% |
| 41.94% | 1.46% | |
| Net Margin | -296.79% | -123.63% |
| 24.81% | 58.34% |
9 Analysts have issued a sales forecast Nektar Therapeutics 2024 . The average Nektar Therapeutics sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Nektar Therapeutics 2024 . The average Nektar Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Nektar Therapeutics Analysts have issued a net profit forecast 2024. The average Nektar Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.45 | -0.71 |
| 26.40% | 51.03% | |
| P/E | negative | |
| EV/Sales | 1.02 |
9 Analysts have issued a Nektar Therapeutics forecast for earnings per share. The average Nektar Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Nektar Therapeutics stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Nektar Therapeutics...
Current Nektar Therapeutics Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 25 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 13 2025 |
| B. Riley Securities | Locked ➜ Locked | Locked | Jan 08 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Nov 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
B. Riley Securities: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Nov 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
